5017 |
Transcatheter Mitral Valve Replacement: Current Evidence and Experience |
Jian (James) Ye |
Apr. 27. 19 |
5016 |
Mitral Valve-in-Valve and Valve-in-Ring: Outcomes and Procedural Considerations |
Vinayak Bapat |
Apr. 27. 19 |
5015 |
QOL Outcomes of the COAPT Trial |
David Joel Cohen |
Apr. 27. 19 |
5014 |
The COAPT Trial: How the Trial Succeed? |
Gregg W. Stone |
Apr. 27. 19 |
5013 |
The REDUCE-FMR Trial |
Horst Sievert |
Apr. 27. 19 |
5012 |
Pathophysiological Types and Biomarkers of Acute Myocardial Infarction |
Buxing Chen |
Apr. 27. 19 |
5011 |
The MITRA-FR Trial: Why the Trial Fails? |
Thierry Lefevre |
Apr. 27. 19 |
5010 |
Pharmacotherapy After TAVR: Antiplatelet or Anticoagulation Therapy |
Do-Yoon Kang |
Apr. 27. 19 |
5009 |
Expanding Indication of TAVR: Ongoing Trials and Expectations |
Alan C. Yeung |
Apr. 27. 19 |
5008 |
TAVR in 2019: Appropriate Patient and Device Selection |
Eberhard Grube |
Apr. 27. 19 |